Friday, October 31, 2014

Stifel starts Vitae Pharma at buy

Stifel starts Vitae Pharma at buy

October 20, 2014 by · Leave a Comment 

Tweet Stifel has initiated coverage of Vitae Pharmaceuticals (NASDAQ:VTAE) with a “buy” rating and price target of $14. The stock closed at $6.30 on Friday. “Vitae’s unique technology platform encompasses the unique ability to rationally design clinical candidates and represents the principal competitive advantage of the company,” writes analyst Dr. Brian Klein. He said Vitae’s CONTOUR […]

Dipexium aims to have first topical antibiotic approved for DFI

Dipexium aims to have first topical antibiotic approved for DFI

September 2, 2014 by · Leave a Comment 

Tweet Dipexium (NASDAQ:DPRX) is enrolling patients in two pivotal Phase 3 trials of its Locilex topical antibiotic in what it hopes will be the first FDA-approved antibiotic topical cream for the treatment of mild infections of diabetic foot ulcers. “Current treatments used off-label to treat mild diabetic foot infections (DFI) generate systemic resistance, exhibit poor […]

WB starts Tandem Diabetes Care at outperform

WB starts Tandem Diabetes Care at outperform

July 15, 2014 by · Leave a Comment 

Tweet William Blair has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with an “outperform” rating and “aggressive growth” profile. The stock closed at $13.37 on Tuesday. Tandem Diabetes makes and markets a durable, tube-based insulin pump with an easy to train and use touch screen user interface to treat Type 1 and potentially Type 2 […]

HCW starts Transition Therapeutics at buy

HCW starts Transition Therapeutics at buy

July 15, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) with a “buy” rating and 12-month price target of $10. The stock closed at $6.58 on Monday. Transition has two molecules in clinical evaluation in three indications. ELND005 is a small molecule in Phase 2 for Alzheimer’s disease (AD) associated agitation, and Down syndrome […]

Pivotal’s fight against fat gains media exposure

Pivotal’s fight against fat gains media exposure

June 25, 2014 by · Leave a Comment 

Tweet The latest issue of Bio Business magazine includes an article about the global obesity epidemic that highlights the efforts of Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to tackle the problem by focusing on the development of Omega-3 therapies and diagnostics. “The consequences of an Omega-3 deficiency could be obesity, diabetes, elevated triglycerides, high cholesterol and coronary heart […]

Transition, Lilly begin Phase 2 diabetes study

Transition, Lilly begin Phase 2 diabetes study

May 15, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) announced the dosing of the first patient in a Phase 2 clinical study of TT-401, a drug candidate for the treatment of Type 2 diabetes. The study is expected to enroll up to 375 Type 2 diabetes subjects and will be performed by Transition’s development partner, Eli Lilly (NYSE:LLY). The objectives […]

Transition moves into late-stage drug development

Transition moves into late-stage drug development

March 18, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005. “We’re maybe a year away from seeing the results of ELND005 in two Phase 2 trials for the treatment of agitation/aggression in patients with mild-to-severe Alzheimer’s disease (AD), and as an […]

Boston Therapeutics planning pivotal trial

Boston Therapeutics planning pivotal trial

December 10, 2013 by · Leave a Comment 

Tweet Boston Therapeutics (OTCQB:BTHE) hopes to begin a pivotal Phase 3 trial, by the second or third quarter of 2014, of a chewable tablet that is designed to be taken before meals to reduce post-meal elevation of blood glucose in Type 2 diabetics. “Our PAZ320 drug is a potential adjunct to metformin in patients living […]

Stifel starts Tandem Diabetes at buy

Stifel starts Tandem Diabetes at buy

December 9, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=h6pWELJ4nYs’]

Tweet Stifel Nicolas has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a “buy” rating and $30 price target, saying the company appears poised for dramatic growth with what “we view as a compelling differentiated platform technology, and a highly visible pipeline in the large, growing, and arguably under-penetrated insulin pump market.” Shares of Tandem […]

In conversation with Kelly Close

In conversation with Kelly Close

September 24, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=TQmt739ynr4′]

Tweet As president and founder of Close Concerns, a healthcare information firm focused on diabetes and obesity, Kelly Close says her passion comes from her extensive professional work as well as her personal experience, contracting Type 1 diabetes 25 years ago. Prior to starting Close Concerns, she worked in the financial sector, including stints as […]

Next Page »

Email Newsletters with Constant Contact
Google+